Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose alkylating chemotherapy for oligometastatic homologous recombination-deficient breast cancer
NL-OMON50592Phase 3Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Jul 2012
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin, thiotepa and cyclophosphamide in breast cancer (3 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Event-free survival. Started Jul 2012; status: completed.
02
Drugs
carboplatinthiotepacyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON50592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50592.